Description

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that modulates incretin hormones to improve glycemic control. It is widely utilized in glucose metabolism, insulin signaling, and type 2 diabetes research models.

This Mingxin formulation provides 50mg per tablet, with a total of 28 tablets per box. The compound is ideal for preclinical experiments, in vitro or in vivo, where incretin dynamics and blood glucose regulation are of interest.

?? For laboratory research only. Not for human or veterinary use.

Product Specifications

Mechanism & Research Applications

Vildagliptin inhibits DPP-4, an enzyme responsible for degrading incretin hormones such as GLP-1 and GIP. By preventing this breakdown, it enhances incretin activity, promoting insulin secretion and reducing glucagon levels in glucose-dependent manners.

This mechanism supports its research use in:

• Type 2 diabetes mellitus (T2DM) experimental models

• Incretin hormone dynamics and signaling pathways

• Beta-cell function and insulin secretion studies

• Combination studies with other antidiabetic compounds

• Glycemic regulation and metabolic profiling

Observed Effects in Research Models

In preclinical environments, vildagliptin has been shown to:

• Enhance glucose-stimulated insulin secretion

• Reduce fasting and postprandial blood glucose

• Preserve pancreatic ?-cell function

• Increase active GLP-1 concentrations

Safety & Handling

• Use Restriction: Laboratory research use only

• Protective Equipment: Gloves, goggles, and lab coat recommended

• Storage: Keep sealed below 25°C, protected from moisture and light

• Disposal: Dispose of as per institutional chemical waste protocols

Research Use Disclaimer

This product is designated exclusively for laboratory research purposes. It is not approved for clinical, diagnostic, or veterinary use. Proper handling, storage, and disposal must follow institutional biosafety standards.